Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679991 · ClinicalTrials.gov registry record · Phase 1
A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients
A Phase 1 study, sponsored by Proteon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00679991 is a Phase 1 study that has completed, run by Proteon Therapeutics. The registered enrollment target is 66 participants.
The verdict
NCT00679991, a Phase 1 study, has completed, sponsored by Proteon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
PRT-201 is a protein that causes long lasting dilation of blood vessels when applied to the outside surface of the blood vessel. The purpose of this study is to determine if PRT-201, when applied to a limited segment of blood vessel immediately after surgery to create an arteriovenous fistula (AVF), is safe, dilates the blood vessel, and increases blood flow through the AVF.
Interventions
- DRUG PRT-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679991
The ClinicalTrials.gov registry entry for NCT00679991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Proteon Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT-201 is the first listed.
NCT00679991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679991 about?
NCT00679991 is a clinical study titled "A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients". PRT-201 is a protein that causes long lasting dilation of blood vessels when applied to the outside surface of the blood vessel. The purpose of this study is to determine if PRT-201, when applied to a limited segment of blood vessel immediately after surgery to create an arteriovenous fistula (AVF),...
What is the current status of trial NCT00679991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2008-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00679991?
The interventions under investigation include: PRT-201 (DRUG).
Who is sponsoring clinical trial NCT00679991?
This trial is sponsored by Proteon Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.